Pub Date : 2026-01-07DOI: 10.1016/j.gore.2026.102026
Claudia Marie S. Watkins , Mojtaba Allahifard , Juan Cattoni , Lauren Montemorano
{"title":"Severe leukemoid reaction and spontaneous tumor lysis syndrome in a young patient with undifferentiated Lynch syndrome-associated ovarian cancer","authors":"Claudia Marie S. Watkins , Mojtaba Allahifard , Juan Cattoni , Lauren Montemorano","doi":"10.1016/j.gore.2026.102026","DOIUrl":"10.1016/j.gore.2026.102026","url":null,"abstract":"","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102026"},"PeriodicalIF":1.3,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145920936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Oncologically safe minimally invasive management of a 25 cm cystic abdominopelvic mass using contained, controlled drainage and removal","authors":"Yasmin Abozenah , Michelle Greenman , Ashley Goreshnik , Gary Altwerger","doi":"10.1016/j.gore.2025.102014","DOIUrl":"10.1016/j.gore.2025.102014","url":null,"abstract":"","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102014"},"PeriodicalIF":1.3,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145972992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dermatofibrosarcoma protuberans (DFSP) is a rare, locally aggressive soft tissue sarcoma characterized by a high risk of local recurrence. Vulvar involvement is exceedingly uncommon and often misdiagnosed as a bening lesion, resulting in delayed diagnosis. Complete surgical excision with negative margins is essential but can be challenging in anatomically sensitive areas as the vulva.
Case presentation
A 55-year-old Puerto Rican woman presented with a slowly enlarging lesion of the left labia majora that was initially managed as a furuncle. Progressive growth and symptoms prompted biopsy, which confirmed DFSP. Staging imaging revealed no metastatic disease. The patient underwent a single-stage left radical hemivulvectomy with immedate reconstruction using a V-Y fasciocutaneous advancement flap. Histopathologic examination demonstrated classic DFSP with uniform spindle cellls in a storiform pattern, stong diffuse CD34 positivity, and negative surgical margins. Postoperative recovery was uncomplicated, with excellent wound healing and flap viability.
Conclusion
This case emphasizes the importance of early biopsy of persistent vulvar lesions and highlights the role of multidiciplinary surgical planning. Single-stage radical excision with immediate reconstruction can achieve favorable oncologic and functional outcomes in vulvar DFSP. Long-term surveillance remains essential due to the potential for late local recurrence.
{"title":"Vulvar dermatofibrosarcoma protuberans in a 55-year-old female: A case report, surgical reconstruction approach and literature review","authors":"Amanda Detrés , Itzamar Pastrana , Marjolaine Suárez , Ricardo Gómez","doi":"10.1016/j.gore.2026.102024","DOIUrl":"10.1016/j.gore.2026.102024","url":null,"abstract":"<div><h3>Background</h3><div>Dermatofibrosarcoma protuberans (DFSP) is a rare, locally aggressive soft tissue sarcoma characterized by a high risk of local recurrence. Vulvar involvement is exceedingly uncommon and often misdiagnosed as a bening lesion, resulting in delayed diagnosis. Complete surgical excision with negative margins is essential but can be challenging in anatomically sensitive areas as the vulva.</div></div><div><h3>Case presentation</h3><div>A 55-year-old Puerto Rican woman presented with a slowly enlarging lesion of the left labia majora that was initially managed as a furuncle. Progressive growth and symptoms prompted biopsy, which confirmed DFSP. Staging imaging revealed no metastatic disease. The patient underwent a single-stage left radical hemivulvectomy with immedate reconstruction using a V-Y fasciocutaneous advancement flap. Histopathologic examination demonstrated classic DFSP with uniform spindle cellls in a storiform pattern, stong diffuse CD34 positivity, and negative surgical margins. Postoperative recovery was uncomplicated, with excellent wound healing and flap viability.</div></div><div><h3>Conclusion</h3><div>This case emphasizes the importance of early biopsy of persistent vulvar lesions and highlights the role of multidiciplinary surgical planning. Single-stage radical excision with immediate reconstruction can achieve favorable oncologic and functional outcomes in vulvar DFSP. Long-term surveillance remains essential due to the potential for late local recurrence.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102024"},"PeriodicalIF":1.3,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145921637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-30DOI: 10.1016/j.gore.2025.102018
Harriet Rothschild, Kelsey Keverline, Sara McKinney, Maureen Farrell, Minhazur Sarker
Objectives
Many reproductive-aged individuals use social media platforms to gather medical advice or find community. TikTok is one of the fastest growing social media platforms and used by many reproductive-aged individuals.
Methods
We evaluated the top 100 English-language videos on cervical cancer screening and dysplasia treatment for relevance to the hashtag and content quality and accuracy.
Results
Among the included videos, most of the content highlighted patients’ personal experiences and provided little medical educational value. Notably, the videos created by medical professionals were higher quality and more often contained accurate health information.
Conclusions
This study highlights the need to increase content quality on TikTok to raise awareness and uptake for cervical cancer screening and treatment in reproductive-aged individuals.
{"title":"From #cervicalcancerscreening to #LEEP – Quality and accuracy of cervical cancer content on TikTok","authors":"Harriet Rothschild, Kelsey Keverline, Sara McKinney, Maureen Farrell, Minhazur Sarker","doi":"10.1016/j.gore.2025.102018","DOIUrl":"10.1016/j.gore.2025.102018","url":null,"abstract":"<div><h3>Objectives</h3><div>Many reproductive-aged individuals use social media platforms to gather medical advice or find community. TikTok is one of the fastest growing social media platforms and used by many reproductive-aged individuals.</div></div><div><h3>Methods</h3><div>We evaluated the top 100 English-language videos on cervical cancer screening and dysplasia treatment for relevance to the hashtag and content quality and accuracy.</div></div><div><h3>Results</h3><div>Among the included videos, most of the content highlighted patients’ personal experiences and provided little medical educational value. Notably, the videos created by medical professionals were higher quality and more often contained accurate health information.</div></div><div><h3>Conclusions</h3><div>This study highlights the need to increase content quality on TikTok to raise awareness and uptake for cervical cancer screening and treatment in reproductive-aged individuals.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102018"},"PeriodicalIF":1.3,"publicationDate":"2025-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146022728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-29DOI: 10.1016/j.gore.2025.102017
Nikita Bastin , Halle Petrie , Marc Robinson , Amir Javid , Robin Lane , Taryn Boucher , Alaina J. Brown , Lauren S. Prescott , Elizabeth Phillips , Ronald D. Alvarez , Marta Crispens , Cosby A. Stone
Objectives
To compare survival between gynecologic cancer patients with carboplatin hypersensitivity thereafter managed with carboplatin desensitization, cisplatin replacement, and alternative non-platinum therapy.
Methods
A retrospective review of patients who experienced a hypersensitivity reaction to carboplatin and were treated at the same comprehensive cancer center between 2010 and 2024 was completed. The primary analysis compared progression-free survival between carboplatin desensitization, cisplatin substitution, and alternative non-platinum therapy patients. Secondary analysis compared survival between platinum therapy and non-platinum alternative therapy patients. Descriptive analysis was further performed to delineate the clinical phenotypes of patients with carboplatin hypersensitivity.
Results
There were 47 gynecologic cancer patients with carboplatin hypersensitivity, and 38 patients with known progression-free survival. Progression-free survival was significantly longer in desensitized patients (31.1 months) vs. cisplatin patients (22.0 months, p = 0.045). There were no significant differences in progression-free survival between desensitized (31.3 months) and alternative therapy patients (36.0 months), as well as platinum (31.1 months) and non-platinum-based alternative therapy patients (36.0 months). A majority of our cohort was observed to have recurrent disease at the time of hypersensitivity (70.2 %), a carboplatin-free interval of 12 months or more (57.4 %), history of adverse reactions to other drugs (76.6 %), advanced stage disease (78.8 %), and serous histology (70.2 %).
Conclusions
Desensitized patients demonstrated increased progression-free survival as compared to cisplatin patients. This progression-free survival advantage may be due to the increased toxicity profiles noted for cisplatin and comparatively better tolerability of carboplatin desensitization. Progression-free survival was similar between carboplatin-desensitized and alternative therapy patients, as well as platinum-based and alternative therapy patients.
{"title":"Impact of carboplatin desensitization therapy on progression-free survival in gynecologic cancers","authors":"Nikita Bastin , Halle Petrie , Marc Robinson , Amir Javid , Robin Lane , Taryn Boucher , Alaina J. Brown , Lauren S. Prescott , Elizabeth Phillips , Ronald D. Alvarez , Marta Crispens , Cosby A. Stone","doi":"10.1016/j.gore.2025.102017","DOIUrl":"10.1016/j.gore.2025.102017","url":null,"abstract":"<div><h3>Objectives</h3><div>To compare survival between gynecologic cancer patients with carboplatin hypersensitivity thereafter managed with carboplatin desensitization, cisplatin replacement, and alternative non-platinum therapy.</div></div><div><h3>Methods</h3><div>A retrospective review of patients who experienced a hypersensitivity reaction to carboplatin and were treated at the same comprehensive cancer center between 2010 and 2024 was completed. The primary analysis compared progression-free survival between carboplatin desensitization, cisplatin substitution, and alternative non-platinum therapy patients. Secondary analysis compared survival between platinum therapy and non-platinum alternative therapy patients. Descriptive analysis was further performed to delineate the clinical phenotypes of patients with carboplatin hypersensitivity.</div></div><div><h3>Results</h3><div>There were 47 gynecologic cancer patients with carboplatin hypersensitivity, and 38 patients with known progression-free survival. Progression-free survival was significantly longer in desensitized patients (31.1 months) vs. cisplatin patients (22.0 months, p = 0.045). There were no significant differences in progression-free survival between desensitized (31.3 months) and alternative therapy patients (36.0 months), as well as platinum (31.1 months) and non-platinum-based alternative therapy patients (36.0 months). A majority of our cohort was observed to have recurrent disease at the time of hypersensitivity (70.2 %), a carboplatin-free interval of 12 months or more (57.4 %), history of adverse reactions to other drugs (76.6 %), advanced stage disease (78.8 %), and serous histology (70.2 %).</div></div><div><h3>Conclusions</h3><div>Desensitized patients demonstrated increased progression-free survival as compared to cisplatin patients. This progression-free survival advantage may be due to the increased toxicity profiles noted for cisplatin and comparatively better tolerability of carboplatin desensitization. Progression-free survival was similar between carboplatin-desensitized and alternative therapy patients, as well as platinum-based and alternative therapy patients.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102017"},"PeriodicalIF":1.3,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145921589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), is an extremely rare and aggressive ovarian malignancy that predominantly affects young women. Prognosis is stage-dependent, with a 5-year overall survival (OS) of approximately 20% in advanced stages (II–IV). Treatment typically involves a multimodal approach.
Case Presentation.
We present the case of a 24-year-old woman diagnosed with stage IV SCCOHT presenting multiple pulmonary nodules and enlarged retroperitoneal lymph nodes. Following standard treatment protocols, including surgery, chemotherapy and high-dose chemotherapy with autologous stem cell rescue, she achieved a complete response and has remained in remission for over five years despite initial pulmonary metastases. Given the rarity of SCCOHT, management was guided by recommendations and through the expertise of a national reference center.
Conclusion
This case highlights that, while durable remission is possible, intensive multimodal therapy is required, and SCCOHT survivors face significant long-term challenges. A comprehensive, multidisciplinary survivorship approach is essential to optimize long-term outcomes and quality of life, in accordance with current guidelines.
{"title":"Long-term remission after multimodal therapy in metastatic small cell carcinoma of the ovary, hypercalcemic type: A case report","authors":"Elora Castanet , Guillaume Goldzak , Geraldine Paraclet , Thomas Grellety","doi":"10.1016/j.gore.2025.102020","DOIUrl":"10.1016/j.gore.2025.102020","url":null,"abstract":"<div><h3>Background</h3><div>Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), is an extremely rare and aggressive ovarian malignancy that predominantly affects young women. Prognosis is stage-dependent, with a 5-year overall survival (OS) of approximately 20% in advanced stages (II–IV). Treatment typically involves a multimodal approach.</div><div>Case Presentation.</div><div>We present the case of a 24-year-old woman diagnosed with stage IV SCCOHT presenting multiple pulmonary nodules and enlarged retroperitoneal lymph nodes. Following standard treatment protocols, including surgery, chemotherapy and high-dose chemotherapy with autologous stem cell rescue, she achieved a complete response and has remained in remission for over five years despite initial pulmonary metastases. Given the rarity of SCCOHT, management was guided by recommendations and through the expertise of a national reference center.</div></div><div><h3>Conclusion</h3><div>This case highlights that, while durable remission is possible, intensive multimodal therapy is required, and SCCOHT survivors face significant long-term challenges. A comprehensive, multidisciplinary survivorship approach is essential to optimize long-term outcomes and quality of life, in accordance with current guidelines.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102020"},"PeriodicalIF":1.3,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145921662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-27DOI: 10.1016/j.gore.2025.102016
Ana Paola Mata Zetina , Sritha Rajupet , Theodore Strange , Adi Davidov , Meekoo Dhar , Lohitha Dhulipalla , Thomas Gut , Kathleen H. Scarbrough , Mario R. Castellanos
Objective
To evaluate rising vulvar cancer incidence in the United States, particularly in individuals aged ≥55, and assess whether increases are driven by HPV-positive or HPV-negative disease.
Methods
We analyzed vulvar cancer incidence trends from 2000 to 2020 using data from the National Cancer Institute’s SEER program, covering 47.9 % of the U.S. population. Cases were classified as HPV-positive or HPV-negative, and age groups were stratified as <55, 55–64, and 65 + . Linear regression analyses assessed trends and racial/ethnic disparities, with statistical significance set at p < 0.05.
Results
Vulvar cancer incidence increased significantly among individuals aged ≥55 from 2000 to 2020 (p < 0.01), with both HPV-positive and HPV-negative cases contributing to this rise. The sharpest increase in HPV-positive cancers occurred in the 55–64 age group, with a 53 % increase, while HPV-negative cancers in this same group rose by 23 %. Individuals aged ≥65 also experienced increases in both subtypes, though to a lesser extent. In contrast, individuals under 55 slightly declined in HPV-positive (1.5 %) and HPV-negative (5 %) cases over the same period.
Conclusion
The rising incidence of both HPV-positive and HPV-negative vulvar cancer among individuals aged ≥55 reflects shifting trends in disease burden. These findings align with prior SEER analyses showing an in situ diagnoses decline and a rise in invasive cases. In the absence of standardized screening guidelines for vulvar cancer, our results underscore the importance of continued surveillance and risk-based gynecologic evaluation strategies in older populations.
{"title":"Rising U.S. trends in HPV-positive and HPV-negative vulvar cancer in older adults, 2000–2020","authors":"Ana Paola Mata Zetina , Sritha Rajupet , Theodore Strange , Adi Davidov , Meekoo Dhar , Lohitha Dhulipalla , Thomas Gut , Kathleen H. Scarbrough , Mario R. Castellanos","doi":"10.1016/j.gore.2025.102016","DOIUrl":"10.1016/j.gore.2025.102016","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate rising vulvar cancer incidence in the United States, particularly in individuals aged ≥55, and assess whether increases are driven by HPV-positive or HPV-negative disease.</div></div><div><h3>Methods</h3><div>We analyzed vulvar cancer incidence trends from 2000 to 2020 using data from the National Cancer Institute’s SEER program, covering 47.9 % of the U.S. population. Cases were classified as HPV-positive or HPV-negative, and age groups were stratified as <55, 55–64, and 65 + . Linear regression analyses assessed trends and racial/ethnic disparities, with statistical significance set at p < 0.05.</div></div><div><h3>Results</h3><div>Vulvar cancer incidence increased significantly among individuals aged ≥55 from 2000 to 2020 (p < 0.01), with both HPV-positive and HPV-negative cases contributing to this rise. The sharpest increase in HPV-positive cancers occurred in the 55–64 age group, with a 53 % increase, while HPV-negative cancers in this same group rose by 23 %. Individuals aged ≥65 also experienced increases in both subtypes, though to a lesser extent. In contrast, individuals under 55 slightly declined in HPV-positive (1.5 %) and HPV-negative (5 %) cases over the same period.</div></div><div><h3>Conclusion</h3><div>The rising incidence of both HPV-positive and HPV-negative vulvar cancer among individuals aged ≥55 reflects shifting trends in disease burden. These findings align with prior SEER analyses showing an in situ diagnoses decline and a rise in invasive cases. In the absence of standardized screening guidelines for vulvar cancer, our results underscore the importance of continued surveillance and risk-based gynecologic evaluation strategies in older populations.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102016"},"PeriodicalIF":1.3,"publicationDate":"2025-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145972991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-26DOI: 10.1016/j.gore.2025.102019
Amrita Mukherjee , Natalie Ayoub , Lanfang Xu , Kimberly L. Cannavale , Elizabeth A. Szamreta , Matthew J. Monberg , Melissa Hodeib , Chun R. Chao
Objectives
We evaluated the impact of the COVID-19 pandemic on healthcare utilization and short-term safety outcomes in ovarian cancer patients.
Study design
Retrospective cohort study.
Methods
Epithelial ovarian cancer patients (n = 799) diagnosed between 01/01/2017–06/30/2021 at Kaiser Permanente Southern California were included. Pre-pandemic and pandemic periods were defined using 03/04/2020 (implementation of stay-at-home order in California) as the cut-off. Care utilization outcomes included the number of office and virtual visits per person-month, number of CA125, complete blood count, electrolytes, and creatinine tests done for chemotherapy monitoring. Short-term safety outcomes included the number of emergency room (ER) visits and hospitalizations per person-month. Negative binomial models were used to evaluate associations.
Results
Overall, 72.7 % and 27.3 % of the patients were diagnosed during the pre-pandemic and pandemic period, respectively. Mean (S.D.) number of office visits per person-month decreased during the pandemic period [0.4 (0.5) vs 0.6 (0.6) in pre-pandemic, p-value < 0.01]. Mean number of virtual visits increased during the pandemic [0.4 (0.7) vs 0.2 (0.3) in pre-pandemic, p-value < 0.01]. The number of virtual visits was twice during the pandemic vs the pre-pandemic period [adjusted-rate ratio (95 %CI): 2.04 (1.54–2.72)]. No differences in ER visits were observed by pandemic periods. Hospitalization rate was lower during the pandemic [adjusted-RR (95 %CI): 0.85 (0.72–1.00)]. In patients who received chemotherapy (n = 684), no differences in chemotherapy monitoring were observed.
Conclusions
Despite a shift from office visits to virtual visits during COVID-19, no differences in laboratory monitoring of chemotherapy and no increase in ER visits and hospitalizations were observed in ovarian cancer patients.
{"title":"COVID-19 pandemic and healthcare utilization in ovarian cancer patients","authors":"Amrita Mukherjee , Natalie Ayoub , Lanfang Xu , Kimberly L. Cannavale , Elizabeth A. Szamreta , Matthew J. Monberg , Melissa Hodeib , Chun R. Chao","doi":"10.1016/j.gore.2025.102019","DOIUrl":"10.1016/j.gore.2025.102019","url":null,"abstract":"<div><h3>Objectives</h3><div>We evaluated the impact of the COVID-19 pandemic on healthcare utilization and short-term safety outcomes in ovarian cancer patients.</div></div><div><h3>Study design</h3><div>Retrospective cohort study.</div></div><div><h3>Methods</h3><div>Epithelial ovarian cancer patients (n = 799) diagnosed between 01/01/2017–06/30/2021 at Kaiser Permanente Southern California were included. Pre-pandemic and pandemic periods were defined using 03/04/2020 (implementation of stay-at-home order in California) as the cut-off. Care utilization outcomes included the number of office and virtual visits per person-month, number of CA125, complete blood count, electrolytes, and creatinine tests done for chemotherapy monitoring. Short-term safety outcomes included the number of emergency room (ER) visits and hospitalizations per person-month. Negative binomial models were used to evaluate associations.</div></div><div><h3>Results</h3><div>Overall, 72.7 % and 27.3 % of the patients were diagnosed during the pre-pandemic and pandemic period, respectively. Mean (S.D.) number of office visits per person-month decreased during the pandemic period [0.4 (0.5) vs 0.6 (0.6) in pre-pandemic, p-value < 0.01]. Mean number of virtual visits increased during the pandemic [0.4 (0.7) vs 0.2 (0.3) in pre-pandemic, p-value < 0.01]. The number of virtual visits was twice during the pandemic vs the pre-pandemic period [adjusted-rate ratio (95 %CI): 2.04 (1.54–2.72)]. No differences in ER visits were observed by pandemic periods. Hospitalization rate was lower during the pandemic [adjusted-RR (95 %CI): 0.85 (0.72–1.00)]. In patients who received chemotherapy (n = 684), no differences in chemotherapy monitoring were observed.</div></div><div><h3>Conclusions</h3><div>Despite a shift from office visits to virtual visits during COVID-19, no differences in laboratory monitoring of chemotherapy and no increase in ER visits and hospitalizations were observed in ovarian cancer patients.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102019"},"PeriodicalIF":1.3,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145972990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-26DOI: 10.1016/j.gore.2025.102015
Susie Cho , Kenneth Pike , Seth Wolpin , Mihkai Wickline , Holly Tomashek , Donna L Berry , Barbara A Goff
Background
In the advanced ovarian cancer setting (AOC), palliative care (PC) is appropriate for virtually every patient. The objectives of this study were 1) to compare referral and visit rates to PC services, pre and post implementation of the electronic Self-Assessment and Care (eSAC) application, in both a prospective study sample and for the institutional population of patients with advanced ovarian cancer; and 2) explore patients’ experiences integrating PC into their medical care.
Methods
Participants remotely submitted symptom and quality of life (QOL) reports about 5 days prior to clinic visits. Moderate-severe symptoms or QOL reports triggered teaching modules, including PC, and clinicians received summary reports with a PC prompt. PC rates were calculated for the prospective sample participants. Pre- and post-study rates for PC were compared using two-sample tests of proportions in the institutional population. A purposive sample of participants who triggered PC referral recommendations were recruited for semi-structured, telephone interviews to explore their experiences with PC integration. Reflexive thematic analysis was conducted to analyze interview data.
Results
In the prospective sample, 145/165 (88 %) patients enrolled; 120 submitted ≥1 report. 78/120 (65 %) participants triggered the PC referral recommendation on ≥1 report; 46 of 78 (59 %) were referred to PC and 49 (63 %) had an initial PC visit by six weeks after the end of the enrollment period. From pre-to-post implementation, institutional PC referral rates increased from 8.6 % to 12.8 % (p = 0.014). Rates of having a PC visit were not significant between pre- and post-implementation. Thirteen participants completed qualitative interviews. Two primary domains emerged: cancer care narratives, and perceptions of PC integration. Key barriers to PC engagement included limited understanding of PC scope, perception of adequate current care, and concerns about care burden and appointment fatigue.
Conclusions
Implementation of eSAC may have impacted the institutional referral rates for PC but did not result in a significant increase in visits. In study participants who triggered a referral, 63 % attended at least one PC visit. Qualitative findings revealed significant barriers to PC engagement including limited understanding of PC services and perceived care burden.
{"title":"A web-based application to promote palliative care in advanced ovarian cancer: A pre-post design","authors":"Susie Cho , Kenneth Pike , Seth Wolpin , Mihkai Wickline , Holly Tomashek , Donna L Berry , Barbara A Goff","doi":"10.1016/j.gore.2025.102015","DOIUrl":"10.1016/j.gore.2025.102015","url":null,"abstract":"<div><h3>Background</h3><div>In the advanced ovarian cancer setting (AOC), palliative care (PC) is appropriate for virtually every patient. The objectives of this study were 1) to compare referral and visit rates to PC services, pre and post implementation of the electronic Self-Assessment and Care (eSAC) application, in both a prospective study sample and for the institutional population of patients with advanced ovarian cancer; and 2) explore patients’ experiences integrating PC into their medical care.</div></div><div><h3>Methods</h3><div>Participants remotely submitted symptom and quality of life (QOL) reports about 5 days prior to clinic visits. Moderate-severe symptoms or QOL reports triggered teaching modules, including PC, and clinicians received summary reports with a PC prompt. PC rates were calculated for the prospective sample participants. Pre- and post-study rates for PC were compared using two-sample tests of proportions in the institutional population. A purposive sample of participants who triggered PC referral recommendations were recruited for semi-structured, telephone interviews to explore their experiences with PC integration. Reflexive thematic analysis was conducted to analyze interview data.</div></div><div><h3>Results</h3><div>In the prospective sample, 145/165 (88 %) patients enrolled; 120 submitted ≥1 report. 78/120 (65 %) participants triggered the PC referral recommendation on ≥1 report; 46 of 78 (59 %) were referred to PC and 49 (63 %) had an initial PC visit by six weeks after the end of the enrollment period. From pre-to-post implementation, institutional PC referral rates increased from 8.6 % to 12.8 % (p = 0.014). Rates of having a PC visit were not significant between pre- and post-implementation. Thirteen participants completed qualitative interviews. Two primary domains emerged: cancer care narratives, and perceptions of PC integration. Key barriers to PC engagement included limited understanding of PC scope, perception of adequate current care, and concerns about care burden and appointment fatigue.</div></div><div><h3>Conclusions</h3><div>Implementation of eSAC may have impacted the institutional referral rates for PC but did not result in a significant increase in visits. In study participants who triggered a referral, 63 % attended at least one PC visit. Qualitative findings revealed significant barriers to PC engagement including limited understanding of PC services and perceived care burden.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102015"},"PeriodicalIF":1.3,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145921588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号